Publications by authors named "E Javouhey"
Background: Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long-acting monoclonal antibody to prevent RSV-associated lower respiratory tract infections (LRTI) was available from September 2023. We described RSV-associated LRTI hospitalisations during the 2023-2024 season among infants younger than six months born at the Hospices Civils de Lyon (HCL), and evaluated the effectiveness of Nirsevimab against RSV-LRTI hospitalisation.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers analyzed data from 361 infants with confirmed pertussis, finding that 32 (9%) developed fulminant symptoms, which were more common in neonates, unvaccinated, and premature infants.
- * Results indicated that B. pertussis strains that produced PRN were associated with higher risks of fulminant pertussis, suggesting the significance of PRN in the severity of the disease.
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for an important mortality rate worldwide. We aimed to evaluate the actual imputability of SARS-CoV-2 on the mortality rate associated with SARS-CoV-2-related illnesses in the pediatric intensive care unit (PICU). Secondary objectives were to identify risk factors for death.
View Article and Find Full Text PDFBackground: Stress cardiomyopathy (Takotsubo syndrome) defined as Takotsubo syndrome is defined as a reversible acute myocardial syndrome with myocardial injury with regional wall motion abnormality and no coronary explanations in the context of stress. The pathophysiology remains partially unknown, and these cases are probably underestimated in paediatrics. We report six cases of Takotsubo probably secondary to neurological damage.
View Article and Find Full Text PDFArticle Synopsis
- Toxic shock syndrome (TSS) is a serious but rare illness that can lead to significant health problems, especially in children, and the study aimed to test the effectiveness and safety of intravenous immunoglobulin (IG) therapy compared to a control treatment in pediatric patients.
- The study involved a randomized clinical trial with 28 participants aged 1 month to 18 years, assessing the feasibility of the trial based on inclusion rates, protocol compliance, and data completeness over a follow-up period of one year.
- The results indicated that while the trial was feasible with a high inclusion rate and low missing data, there was no significant difference in clinical outcomes between the IG and control groups, although more adverse events were noted in the control group.